New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
10:33 EDTOLED, ICPT, RPTP, VNDA, UBNT, ZU, RAX, MNKD, ARWROptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
News For RPTP;ARWR;ZU;ICPT;MNKD;UBNT;OLED;RAX;VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 28, 2014
05:49 EDTMNKDStocks with implied volatility movement; SDRL MNKD
Stocks with implied volatility movement; Seadrill (SDRL) 74, MannKind (MNKD) 53 according to iVolatility.
November 26, 2014
10:12 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: VNET GME ARWR GMCR SGMS DSW DANG ARUN JMEI MBLY
November 24, 2014
10:00 EDTRAXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:32 EDTRAXRackspace downgraded to Equal Weight at Stephens
Subscribe for More Information
07:58 EDTRAXRackspace downgraded to Equal Weight from Overweight at Stephens
November 21, 2014
05:52 EDTMNKDStocks with implied volatility movement; MNKD LOCO
Subscribe for More Information
05:39 EDTMNKDMannKind, Sanofi on track to launch Afrezza in Q1, says Piper Jaffray
Subscribe for More Information
November 20, 2014
18:21 EDTRAXOn The Fly: After Hours Movers
Subscribe for More Information
17:05 EDTRAXRackspace founder, Chairman Graham Weston purchases $2.5M of company stock
Subscribe for More Information
November 19, 2014
10:00 EDTRAXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:36 EDTRAXRackspace initiated with an Overweight at Barclays
Subscribe for More Information
November 18, 2014
07:32 EDTARWRArrowhead files for regulatory permission to begin Phase I ARC-AAT trial
Arrowhead Research recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-AAT, for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Pending approval, Arrowhead intends to proceed with a double blind, placebo-controlled dose escalation, Phase 1 study to determine the safety, tolerability, pharmacokinetics and effect on circulating alpha-1 antitrypsin levels of ARC-AAT in healthy volunteers and patients with alpha-1 antitrypsin deficiency. The study is planned to start in Australia in healthy volunteers and will dose escalate until predetermined levels of alpha-1 antitrypsin reduction are reached. Once these levels of protein knockdown are achieved, the study will transition into a population of patients with ZZ genotype alpha-1 antitrypsin deficiency to further evaluate escalating doses of ARC-AAT. The study is designed to enroll up to 48 subjects, including healthy volunteers and alpha-1 antitrypsin deficiency patients. The application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration.
November 17, 2014
12:03 EDTRAXOptions with decreasing implied volatility
Subscribe for More Information
November 14, 2014
16:58 EDTRAXThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
15:22 EDTICPTIntercept CEO says company 'very well-positioned' in terms of balance sheet
Subscribe for More Information
10:10 EDTRAXOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTOLEDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:42 EDTOLEDUniversal Display downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Universal Display to Perform on expectations growth will slow in 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use